The Copenhagen Insulin and Metformin Therapy Trial
Phase 4
Completed
- Conditions
- ArteriosclerosisAtherosclerosisType 2 Diabetes
- Interventions
- Drug: insulin aspart + insulin aspart protamin
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 415
- Registration Number
- NCT00657943
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰Frederiksberg Hospital, Frederiksberg, Denmark
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2008-06-05
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 17
- Registration Number
- NCT00335413
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Phase 4
Completed
- Conditions
- Type 2 DiabetesMicroalbuminuria
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-18
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT00320879
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Copenhagen, Denmark
Irbesartan in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 DiabetesMicroalbuminuriaHypertension
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2006-04-25
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Registration Number
- NCT00317915
Spironolactone in Diabetic Nephropathy
Phase 4
Completed
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2006-04-25
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 48
- Registration Number
- NCT00317954
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy
Phase 4
Completed
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-04-06
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT00311870
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 100
- Registration Number
- NCT00118950
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin BIAsp30 (Novolog 70/30)Drug: Placebo-RepaglinideDrug: Placebo-Metformin
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 102
- Registration Number
- NCT00118963
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 100
- Registration Number
- NCT00118937
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type IDiabetic Nephropathy
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2006-11-23
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 60
- Registration Number
- NCT00118976
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
© Copyright 2025. All Rights Reserved by MedPath